# Differentially Expressed Genes in Head and Neck Squamous Cell Carcinoma: Exploratory Research Using the Cancer Genome Atlas (TCGA) RNA Sequence Data and DESeq2 Package

## TL;DR

This study identifies genes that are abnormally active in head and neck cancer using large-scale genetic data, pointing to potential new treatment targets.

## Contribution

The study identifies novel prognostic markers and candidate therapeutic targets for HNSCC using TCGA RNA-seq data and DESeq2 analysis.

## Key findings

- 10,976 differentially expressed genes were identified, with significant enrichment in cancer-related pathways.
- Genes like HOXC6, NUCB2, and IL12A-AS1 were found to correlate with poorer prognosis in HNSCC patients.
- Up-regulated genes were enriched in pathways like 'Pathway in Cancer' and 'PI3K-Akt signaling', while down-regulated genes were linked to 'Metabolic pathways'.

## Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the most common cancer of the head and neck region, including the oral cavity, larynx, pharynx, nasal cavity, and paranasal sinuses. Cancer arises because of cumulative genetic and epigenetic alterations in cancer-associated genes. It is important to understand the genetic/epigenetic background of the tumors to establish molecular targeted therapies. So far, the knowledge of key genes or molecules, which are closely associated with the carcinogenesis and development of HNSCC, is insufficient for targeted therapies. On the other hand, recent advances in next-generation sequencing (NGS) have greatly contributed to cancer genome research. In this research, using RNA sequence data of HNSCC stored in The Cancer Genome Atlas (TCGA) database, we identified differentially expressed genes (DEGs), functionally enriched gene sets, and new prognostic markers or candidate therapeutic targets. This exploratory study investigated whether novel prognostic markers and candidate therapeutic targets for HNSCC could be identified from TCGA RNA-seq data.

Methods

The RNA sequence data were downloaded from TCGA, including 504 cases from cancer and 44 cases from corresponding normal tissue. The DEGs between cancer and normal samples were detected using the DESeq2 package in R software. Differences with | log2 fold change (FC) | > 1.0 and p-value <0.05 were considered as DEGs. Functional enrichment analyses were performed by ShinyGO 0.85 with Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. A gene set enrichment analysis (GSEA) was also performed using GSEA software. We also analyzed the top 10 up- and down-regulated genes, which were sorted by adjusted p-value, by using Kaplan-Meier analysis to assess their potential as prognostic markers.

Results

Using the DESeq2 package, 10,976 DEGs were detected, including 6,932 up-regulated genes and 4,044 down-regulated genes in cancer. As expected, functional enrichment analyses revealed enrichment of KEGG terms associated with cancers, including “Pathway in Cancer”, “Human Papillomavirus infection”, and “PI3K-Akt signaling pathway” in up-regulated genes, whereas KEGG terms enriched in down-regulated genes were mainly “Metabolic pathways”. GO terms for “Cell differentiation (GOBP)” and “Extracellular region (GOCC)” were enriched both in up- and down-regulated genes, suggesting aberrant expression of genes associated with cell differentiation and remodeling of the extracellular matrix. GSEA data supported the enrichment analyses data. Kaplan-Meier analyses revealed that high expression of homeobox C6 (HOXC6) (p=0.048), nucleobindin 2 (NUCB2) (p=0.007), IL12A antisense RNA 1 (IL12A-AS1) (p=0.001), calcium-binding protein 39-like (CAB39L)(p=0.038), nitric oxide synthase trafficking (NOSTRIN) (p=0.024), SLC8A1 antisense RNA 1 (SLC8A1-AS1) (p=0.016), were the significantly correlated with poorer prognosis.

Conclusions

Based on bioinformatical approaches, we identified significantly enriched gene sets and novel candidates for prognostic markers or therapeutic targets in HNSCC. Further investigation would aid in determining the anti-cancer effects of these candidates.